Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several statements about active ingredient, dosage form, drug-interaction spacing, and common adverse reaction (constipation; plus nausea/abdominal discomfort) are supported by the provided label excerpts. However, multiple claims about clinical indications (e.g., “high cholesterol” generally) and product-to-product differences/taste/dosing/tolerance are not supported by the supplied label text, and some claims are speculative or marketing-like (generic naming/patent tracking) and therefore not label-aligned.
Category Scores
Accurate Statements
Prevalite is the brand name for the bile-acid sequestrant cholestyramine.
Label identifies Prevalite as cholestyramine for oral suspension; mechanism is bile acid binding (Clinical Pharmacology).
A “Prevalite generic” would typically mean a generic version of cholestyramine sold under another name.
No relevant label text provided to confirm or deny generic-naming conventions; however this statement is not directly contradicted by the supplied label excerpts.
The active ingredient is cholestyramine.
Label: “Prevalite® (cholestyramine for oral suspension, USP) powder”.
Cholestyramine is usually a powder or suspension for oral use, depending on the product.
Label for Prevalite: “cholestyramine for oral suspension, USP powder” (Dosage and Administration).
Cholestyramine can reduce absorption of some other drugs.
Drug Interactions: may delay or reduce absorption of concomitant oral medications.
Spacing doses from other medications is often important when using cholestyramine.
Drug Interactions: take other drugs at least 1 hour before or 4 to 6 hours after Prevalite to avoid impeding absorption.
Cholestyramine products commonly cause constipation, bloating, and nausea.
Adverse Reactions: “most common adverse reaction is constipation”; less frequent includes “Abdominal discomfort and/or pain, flatulence, nausea, vomiting...” (bloating/flatulence and nausea are encompassed).
Unsupported Statements
Cholestyramine is used for conditions such as high cholesterol.
The label excerpt specifies reduction of elevated serum cholesterol in primary hypercholesterolemia as adjunctive therapy to diet; the claim is too general and not directly quoted as labeled language.
Cholestyramine is used in some cases for bile-acid–related diarrhea.
Label excerpt provided indicates pruritus associated with partial biliary obstruction and adjunctive therapy for elevated serum cholesterol; no labeled statement about bile-acid–related diarrhea in the supplied text.
When searching for a generic substitute, it is key to search for cholestyramine rather than “Prevalite.”
No label content provided regarding searching for generics/substitution behavior.
In practice, pharmacies typically substitute based on the active ingredient and dosage form.
No label content provided regarding pharmacy substitution practices.
Whether “Prevalite” itself has a generic depends on patent/exclusivity status for the specific branded product and formulation.
No label content provided regarding patents/exclusivity or generic availability.
DrugPatentWatch.com tracks patent and exclusivity information for drugs.
No label content provided about external websites or patent tracking.
Cholestyramine products can differ in how the powder mixes and tastes.
No label content provided about taste/mixing differences between products.
Cholestyramine products can differ in dosing schedule/tolerance.
No label content provided about differences between products’ schedules/tolerance.
Cholestyramine products can differ in total daily amount needed to match response.
No label content provided about between-product variability in titration/response.
Switching cholestyramine products can sometimes change gastrointestinal side effects.
No label content provided about switching between products or effect on side-effect profiles.
Contradictions
Important Omissions
For indication statements, the label specifies particular labeled contexts (adjunctive therapy to diet for primary hypercholesterolemia; may be useful when hypertriglyceridemia coexists but is not indicated where hypertriglyceridemia is the main abnormality of concern; and indication for pruritus associated with partial biliary obstruction).
Importance:
Moderate
No dosage/administration claims were evaluated except powder/suspension form; the label also states starting adult dose (one packet or level scoopful 5.5 g once or twice daily) and that it should not be taken in dry form (must be mixed with water/fluids). These were not included in the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported or non-label claims include an indication for bile-acid–related diarrhea and generalized generic-substitution/patent/taste/product-switch variability, which could mislead regarding labeled uses and expectations. The drug-interaction spacing and common adverse reaction (constipation) are aligned with label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims are not supported by the supplied label excerpts (notably bile-acid–related diarrhea use and product-to-product differences/generic/patent/taste/substitution guidance). Indication language is overly general relative to the label’s specific contexts.
Suggested Improvement
Limit indication statements to the label’s specific indications and phrasing from Indications and Usage; remove or qualify non-label assertions about generic availability, substitution practices, taste/mixing, and switching effects unless supported by the label excerpts provided.